secondary parkinson disease

Summary

Summary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Top Publications

  1. ncbi The diagnosis of Parkinson's disease
    Eduardo Tolosa
    Neurology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet Neurol 5:75-86. 2006
  2. ncbi Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, M13 9PT, United Kingdom
    J Neurosci 21:6853-61. 2001
  3. ncbi Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure
    V N Uversky
    Department of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, USA
    J Biol Chem 276:44284-96. 2001
  4. ncbi Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat
    Alison L McCormack
    The Parkinson s Institute, Sunnyvale, California 94089, USA
    Neurobiol Dis 10:119-27. 2002
  5. ncbi The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor
    Graziella Cappelletti
    Department of Biology, University of Milano, Via Celoria, 26, 20133 Milano, Italy
    FEBS Lett 579:4781-6. 2005
  6. ncbi A Parkinsonian syndrome in methcathinone users and the role of manganese
    Ainars Stepens
    Department of Neurology, Riga Stradins University, Riga, Latvia
    N Engl J Med 358:1009-17. 2008
  7. ncbi Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy
    C H Lyoo
    Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
    Brain 131:438-46. 2008
  8. ncbi Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype
    Mona Thiruchelvam
    Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Eur J Neurosci 18:589-600. 2003
  9. ncbi A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease?
    K Ossowska
    Department of Neuro Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna St, 31 343 Krakow, Poland
    Eur J Neurosci 22:1294-304. 2005
  10. ncbi Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?
    Y Kim
    Department of Occupational and Environmental Medicine, University of Ulsan School of Medicine, Ulsan, South Korea
    Mov Disord 17:568-75. 2002

Research Grants

  1. Divalent Metal Transporter: Role in Manganese Toxicity
    JEROME ROTH; Fiscal Year: 2004
  2. ROLE OF PROTEASOMAL DYSFUNCTION IN PARKINSON'S DISEASE
    KEVIN MCNAUGHT; Fiscal Year: 2008
  3. Blood Brain Barrier Dysfunction in Parkinson's Diseases
    Paul M Carvey; Fiscal Year: 2010
  4. Sleep and Nocturnal Endocrine Function in MDMA User
    Una McCann; Fiscal Year: 2007
  5. Gluthathione Depletion /Mitochondrial Complex I Dysfunct
    Julie Andersen; Fiscal Year: 2006
  6. Organochlorine pesticide, PCBs, and Parkinsons
    Alberto Ascherio; Fiscal Year: 2007
  7. AIDS Neurotherapeutics and BBB Drug Efflux
    William Pardridge; Fiscal Year: 2007
  8. F-18 Synthesizer
    Anna Liisa Brownell; Fiscal Year: 2007
  9. DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS
    Jeffrey Kordower; Fiscal Year: 2006
  10. Dopamine D2 and Adenosine A2A roles:Tremulous Movements
    John Salamone; Fiscal Year: 2007

Detail Information

Publications202 found, 100 shown here

  1. ncbi The diagnosis of Parkinson's disease
    Eduardo Tolosa
    Neurology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet Neurol 5:75-86. 2006
    ..Also genetic testing and various other ancillary tests, such as olfactory testing, MRI, and dopamine-transporter single-photon-emission computed-tomography imaging, help with clinical diagnostic decisions...
  2. ncbi Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease
    E Bezard
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, M13 9PT, United Kingdom
    J Neurosci 21:6853-61. 2001
    ....
  3. ncbi Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure
    V N Uversky
    Department of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, USA
    J Biol Chem 276:44284-96. 2001
    ..The results indicate that low concentrations of some metals can directly induce alpha-synuclein fibril formation...
  4. ncbi Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat
    Alison L McCormack
    The Parkinson s Institute, Sunnyvale, California 94089, USA
    Neurobiol Dis 10:119-27. 2002
    ....
  5. ncbi The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor
    Graziella Cappelletti
    Department of Biology, University of Milano, Via Celoria, 26, 20133 Milano, Italy
    FEBS Lett 579:4781-6. 2005
    ..This paper provides the first evidence that dynamic instability of microtubules is specifically affected by MPP+ and suggests that it could play a role in neuronal cell death underlying PD...
  6. ncbi A Parkinsonian syndrome in methcathinone users and the role of manganese
    Ainars Stepens
    Department of Neurology, Riga Stradins University, Riga, Latvia
    N Engl J Med 358:1009-17. 2008
    ..A distinctive extrapyramidal syndrome has been observed in intravenous methcathinone (ephedrone) users in Eastern Europe and Russia...
  7. ncbi Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy
    C H Lyoo
    Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
    Brain 131:438-46. 2008
    ..Parkinsonian motor deficits precede putaminal hypometabolism that begins in its posterolateral part. Cerebellar hypometabolism occurs early in the clinical courses and seems to be a relevant metabolic descriptor of cerebellar deficits...
  8. ncbi Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype
    Mona Thiruchelvam
    Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Eur J Neurosci 18:589-600. 2003
    ..Collectively, these data demonstrate enhanced sensitivity of the ageing nigrostriatal dopamine pathway to these pesticides, particularly paraquat + maneb, resulting in irreversible and progressive neurotoxicity...
  9. ncbi A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease?
    K Ossowska
    Department of Neuro Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna St, 31 343 Krakow, Poland
    Eur J Neurosci 22:1294-304. 2005
    ....
  10. ncbi Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?
    Y Kim
    Department of Occupational and Environmental Medicine, University of Ulsan School of Medicine, Ulsan, South Korea
    Mov Disord 17:568-75. 2002
    ..Further studies are required to elucidate the relationship between Mn and various forms of parkinsonism...
  11. ncbi Reversible Parkinsonism and T1W pallidal hyperintensities in acute liver failure
    Annu Aggarwal
    Movement Disorder Clinic, Department of Neurology, Jaslok Hospital and Research Centre, Mumbai, India
    Mov Disord 21:1986-90. 2006
    ..Though hitherto unreported, we propose that Parkinsonism with T1W pallidal hyperintensities may not be uncommon in ALF...
  12. ncbi Evaluation of risk of Parkinson's disease in a cohort of licensed pesticide users
    N Vanacore
    Department of Neurological Sciences, La Sapienza University, Viale dell Universita 30, I 00185 Rome, Italy
    Neurol Sci 23:S119-20. 2002
    ..After 27 years of follow-up, 4788 subjects are still alive. The aim of this study is to measure the prevalence of Parkinson's disease in a large group of workers with theoretically increased risk...
  13. ncbi Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration
    Alison L McCormack
    The Parkinson s Institute, Sunnyvale, California 94089, USA
    J Neurochem 85:82-6. 2003
    ..g. amino acids) or therapeutic agents (e.g. l-dopa) may modify the effects of toxicants targeting the nigrostriatal system...
  14. ncbi Liver transplantation in a patient with rapid onset parkinsonism-dementia complex induced by manganism secondary to liver failure
    Giorgio Fabiani
    Department of Neurology, Hospital de Caridade da Irmandade, Santa Casa de Misericórdia de Curitiba, Pontificia Universidade Catolica do Parana, 80035 180 Curitiba, PR, Brazil
    Arq Neuropsiquiatr 65:685-8. 2007
    ..The treatment of this form of parkinsonism is controversial and liver-transplantation should not be considered as first line treatment but as an alternative one...
  15. ncbi Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
    Werner J Schmidt
    Zoological Institute, Neuropharmacology, Mohlstrasse 54 1, University Tübingen, 72074 Tubingen, Germany
    Neurosci Lett 330:251-4. 2002
    ..From the supraadditive effect of the enantiomers it may be concluded that both enantiomers contribute to the antiparkinsonian effects at two different target sites...
  16. ncbi Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet
    M D Lindner
    CytoTherapeutics, Inc, Provicence, RI 02906, USA
    Brain Res Bull 39:367-72. 1996
    ..The results of the present study suggest that it is possible to investigate the therapeutic potential of novel treatments as well as their effects on the therapeutic window of oral Sinemet in this rodent model of Parkinson's disease...
  17. ncbi Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease
    Janice M Phillips
    Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    Eur J Neurosci 23:151-60. 2006
    ..These data suggest that MPEP may act at the level of the STN to reduce glutamatergic overactivity and thereby induce anti-parkinsonian effects...
  18. ncbi Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats
    Yeung Kee Kim
    Department of Rehabilitation Medicine, Oriental Medical Hospital, College of Oriental Medicine, Kyungwon University, 20 8 Songpa dong, Songpa Gu, Seoul 138 170, Republic of Korea
    Neurosci Lett 384:133-8. 2005
    ..These effects of acupuncture were not observed for the non-acupoint (hip) acupuncture. The present study shows that acupuncture at the ST36 acupoint can be used as a useful strategy for the treatment of Parkinson's disease...
  19. ncbi Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors
    Silva Fredduzzi
    Molecular Neurobiology Laboratory, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
    J Neurosci 22:1054-62. 2002
    ..Furthermore, they raise the possibility that the maladaptive dyskinetic responses to chronic l-DOPA treatment in Parkinson's disease may be attenuated by A(2A) receptor inactivation...
  20. ncbi Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence
    Maria C Obinu
    Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S A Vitry sur Seine, France
    Mov Disord 17:13-9. 2002
    ..We conclude that riluzole protects dopaminergic neurons and reduces behavioral deficits in a marmoset model of PD...
  21. ncbi Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease
    Rajnish Kumar Chaturvedi
    Developmental Toxicology Division, Industrial Toxicology Research Centre, Post Box 80, M G Marg, Lucknow, India
    Neurosci Lett 398:44-9. 2006
    ..The results suggest that NGF at the time of transplantation exhibits neuroprotective effect on transplanted VMC as well as neurorescue effect on remaining host nigral dopaminergic neurons, leading to better functional restoration...
  22. ncbi Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease
    Tracey K Murray
    Lilly Research Centre, Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Pharmacol Biochem Behav 73:455-66. 2002
    ..These data suggest that activation of Group II mGlu receptors can provide some protection in models of PD, while their role in providing functional improvement is less clear...
  23. ncbi Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra
    Tinmarla F Oo
    Department of Neurology, The College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Exp Neurol 175:1-9. 2002
    ..It will be important to recognize these differences in the consideration of caspase inhibitors in the treatment of degenerative neurologic disease...
  24. ncbi Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat
    Joanne E Nash
    Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, United Kingdom
    Mov Disord 17:455-66. 2002
    ..These studies are in line with previous findings suggesting that administration of NR2B-selective NMDA receptor antagonists may be therapeutically beneficial for parkinsonian patients, when given de novo and following L-dopa treatment...
  25. ncbi Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area -- model of the early beginning of Parkinson's symptomatology?
    C Heim
    Department of Neuropharmacology and Physiology, Max Planck Institute for Experimental Medicine, Gottingen, Federal Republic of Germany
    J Neural Transm 109:691-709. 2002
    ..The question arises whether the model used here with the partially loss of dopaminergic neurons and fibres reflects some of pathological symptoms of Parkinson's disease in the early states...
  26. ncbi Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice
    Eric K Richfield
    Department of Pathology and Lab Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA
    Exp Neurol 175:35-48. 2002
    ..Expression of hm2alpha-SYN adversely affects the integrity of dopaminergic terminals and leads to age-related declines in motor coordination and dopaminergic markers...
  27. ncbi The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma
    A Castano
    Departamento de Bioquimica, Bromatologia, Toxicologia y Medicina Legal, Universidad de Sevilla, Seville, Spain
    J Neurochem 81:150-7. 2002
    ..This damage may be due, at least in part, to a cascade of events independent of that described for TNF-alpha/IL-1 beta/IFN-gamma...
  28. ncbi Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats
    Diana Reimers
    Servicio de Neurobiologia, Hospital Ramon y Cajal, 28034 Madrid, Spain
    J Histochem Cytochem 54:457-65. 2006
    ..As apomorphine-induced rotational behavior was also reduced in these animals, we propose LGF as a novel factor that, when delivered to the striatum, may be useful in the treatment of Parkinson's disease...
  29. ncbi PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease
    N F Nichols
    Neurobiology Research, Pharmacia Corporation, Kalamazoo, MI 49001, USA
    Neuropharmacology 43:817-24. 2002
    ..These results suggest that PNU-96391A could be therapeutically useful to prevent the development of behavioral sensitization induced by DA agonists...
  30. ncbi Grafts of adult subependymal zone neuronal progenitor cells rescue hemiparkinsonian behavioral decline
    R Mark Richardson
    Department of Neurosurgery, Medical College of Virginia Hospitals, Virginia Commonwealth University Health System, P O Box 980631, Richmond, VA 23298, USA
    Brain Res 1032:11-22. 2005
    ..These results suggest that although neither the normal nor the deafferented striatum alone support the neuronal differentiation of transplanted adult SEZ NPCs, grafts maintaining a progenitor phenotype may produce a therapeutic benefit...
  31. ncbi An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate
    Sheila M Fleming
    Department of Psychology, Institute for Neuroscience, University of Texas, Austin, TX 78712, USA
    Behav Brain Res 156:201-13. 2005
    ..These data suggest that establishing a symptomatic threshold preclinically may help researchers evaluate potential treatments and model individual and group resistance to nigrostriatal insults...
  32. ncbi Neuroprotection by crocetin in a hemi-parkinsonian rat model
    Abdullah Shafique Ahmad
    Neurotoxicology Laboratory, Department of Medical Elementology and Toxicology, Jamia Hamdard Hamdard University, Hamdard Nagar, New Delhi 110062, India
    Pharmacol Biochem Behav 81:805-13. 2005
    ....
  33. ncbi Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease
    Vincent Paille
    INSERM, Unite 437, CHU de Nantes, 30 Bd Jean Monnet, 44093 Nantes, France
    Neuroreport 15:561-4. 2004
    ..Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs...
  34. ncbi Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat
    Jennifer L Taylor
    Cellular and Clinical Neurobiology Program, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Pharmacol Biochem Behav 81:887-93. 2005
    ..01, 0.1 and 1.0 mg/kg), limb (0.1 and 1.0 mg/kg), and orolingual (0.1 and 1.0 mg/kg) AIMs. These results indicate the importance of D1 and D2 receptors to LID and further validate the rat AIMs model...
  35. ncbi Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats
    Eilis Dowd
    Brain Repair Group, School of Biosciences, Cardiff University, Wales, Cardiff CF10 3US, UK
    Behav Brain Res 159:153-61. 2005
    ..This experiment confirms that the lateralised nose-poking task may be a powerful tool for assessment of the nature of deficit and recovery in rats with complete but not partial unilateral dopamine lesions...
  36. ncbi Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease
    Christophe Jollivet
    INSERM ERIT M 0104, Batiment IBT, 10 rue Andre Boquel, 49100 Angers, France
    Neurosci Lett 356:207-10. 2004
    ..Nevertheless, the improvement was not statistically significant at the latest time point due to the spontaneous reinnervation observed in the model used...
  37. ncbi Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats
    Masatoshi Inden
    Department of Neurobiology, Kyoto Pharmaceutical University, Misasagi, Kyoto, Japan
    J Neurochem 95:950-61. 2005
    ..These results suggest that serofendic acid protects against 6-OHDA-induced SNpc dopaminergic neurodegeneration in a rat model of Parkinson's disease...
  38. ncbi Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice
    Xia Li
    Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China
    Chin Med J (Engl) 118:1357-61. 2005
    ..Aging is an accepted risk factor for idiopathic Parkinson's disease. The aim of this study was to test the hypothesis that paraquat could induce PD-like nigrostriatal dopaminergic degeneration in aging C57BL/6 mice...
  39. ncbi Dopaminergic trophism after intrastriatal injection of lentivirus-transferred GDNF in Parkinson rat model
    Bing Sun
    Institutes of Biochemistry and Cell Biology, The Chinese Academy of Sciences, Shanghai 200031, China
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35:937-40. 2003
    ....
  40. ncbi Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys
    Jasmine M Henderson
    Prince of Wales Medical Research Institute, University of New South Wales, Sydney, Australia
    Behav Brain Res 160:267-76. 2005
    ..Our results demonstrate that the SNr is important in body orientation changes in parkinsonism...
  41. ncbi Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice
    Xia Li
    Division of Natural Products Chemistry, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930 0194, Japan
    Pharmacol Biochem Behav 82:345-52. 2005
    ..The present findings suggest that PME has a beneficial influence on parkinsonism induced by PQMB and that the effects of PME are attributable to some substance(s) included in the ethanol-soluble fraction of PME (PME-I)...
  42. ncbi Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF
    Ann D Cohen
    Department of Neurology and Center for Neuroscience, University of Pittsburgh, Philadelphia, USA
    J Neurochem 85:299-305. 2003
    ..These results suggest that preinjury forced limb-use can prevent the behavioral and neurochemical deficits to the subsequent administration of 6-OHDA and that this may be due in part to neuroprotective effects of GDNF...
  43. ncbi Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model
    Hi Joon Park
    Research Group of Pain and Neuroscience, Kyung Hee University, Seoul 130 701, Korea
    Exp Neurol 180:93-8. 2003
    ..In conclusion, we observed that only acupuncturing without the use of any drug has the neuroprotective effects against neuronal death in the rat PD model and these protective properties of acupuncture could be mediated by trkB...
  44. pmc Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys
    Krystof S Bankiewicz
    Department of Neurological Surgery, University of California San Francisco, Mission Center Building 0555, 1855 Folsom Street, Room 230, 94103, USA
    Exp Neurol 197:363-72. 2006
    ..This may be similar to focal dopaminergic activity in PD patients that developed off-drug or "runaway" dyskinesias following fetal mesencephalic grafts...
  45. ncbi Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease
    Yoshitsugu Oiwa
    Molecular Therapeutics Section, Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    J Neurosurg 98:136-44. 2003
    ..To make an extensive lesion, the authors used a convection-enhanced delivery (CED) method for intrastriatal infusion of 6-OHDA and evaluated the animals for a model of Parkinson disease (PD)...
  46. ncbi The mouse MPTP model: gene expression changes in dopaminergic neurons
    Kati Kühn
    Department of Animal Physiology, Ruhr University of Bochum, D 44780 Bochum Biofrontera Pharmaceuticals AG, D 51377 Leverkusen, Germany
    Eur J Neurosci 17:1-12. 2003
    ..All genes investigated were affected. However, alpha-synuclein was the only gene that was exclusively up-regulated in MPTP-treated animals displaying cell death...
  47. ncbi Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct
    Lone Fjord-Larsen
    NsGene A S, Baltorpvej 154, 2750 Ballerup, Denmark
    Exp Neurol 195:49-60. 2005
    ..An in vivo gene therapy approach with a modified NTN construct is therefore a possible treatment option for Parkinson's disease that should be further explored...
  48. ncbi Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease
    Lee Anna Cunningham
    Department of Neurosciences, University of New Mexico School of Medicine, Albuquerque, New Mexico, 87131, USA
    Exp Neurol 174:230-42. 2002
    ..These results indicate that continuous exposure to low levels of GDNF provided by transgenic astrocytes provides marked neuroprotection of nigral dopaminergic neurons. (c)2002 Elsevier Science (USA)...
  49. ncbi Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra
    G Costa
    , , Avda. Italia 3318, 11 600, Montevideo, Uruguay
    Brain Res 888:336-342. 2001
    ..These results are showing that putative neuroprotective effects of nicotine in vivo depend on an acute intermittent administration schedule and on the extent of the brain lesion...
  50. ncbi Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity
    F Dabbeni-Sala
    Department of Pharmacology, University of Padova, 35131 Padova, Italy
    FASEB J 15:164-170. 2001
    ..Melatonin may have potential utility in the treatment of neurodegenerative disorders where oxidative stress is a participant...
  51. ncbi Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model
    Fabio Blandini
    Laboratory of Functional Neurochemistry, IRCCS Neurological Institute C Mondino, Pavia, Italy
    Eur J Neurosci 25:397-405. 2007
    ....
  52. ncbi Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat
    S Breit
    INSERM U 318, Department of Preclinical Neurobiology, Joseph Fourier University, Grenoble, France
    Exp Neurol 205:36-47. 2007
    ..These data suggest that in the GP-STN-GP network, the excitatory influence of the STN-GP pathway overrides that of the GABAergic GP-STN pathway, questioning the classical model of basal ganglia organization...
  53. ncbi Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats
    Elisabetta Tronci
    Department of Toxicology, University of Cagliari, Italy
    Eur J Pharmacol 566:94-102. 2007
    ..Moreover, in agreement to other well characterized adenosine A2A receptor antagonists, ST1535 features antitremorigenic effects...
  54. ncbi Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats
    Myoung Chul Yoon
    Department of Exercise Physiology, Graduate School, Korea University, 1 5 Anam dong, Sungbuk Gu, Seoul 136 701, Republic of Korea
    Neurosci Lett 423:12-7. 2007
    ..The results of the present study show that treadmill exercise may provide therapeutic value for the treatment of Parkinson's disease patients...
  55. ncbi Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism
    Karuppagounder S Senthilkumar
    Division of Cell Biology and Physiology, Laboratory of Clinical and Experimental Neuroscience, Indian Institute of Chemical Biology, 4 Raja S C Mullick Road, Kolkata 700032, India
    Behav Brain Res 184:11-8. 2007
    ..This approach is useful in reducing the oral dose of drugs that are with severe systemic effects, and that develop tolerance...
  56. ncbi Experimental change on dopaminergic neurons in striatum of Parkinson disease rats
    X Y Chen
    School of Pharmacy, Anhui Medical University, Hefei, China
    Histol Histopathol 22:1085-90. 2007
    ....
  57. ncbi Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration
    Virgili Perez
    Laboratori de Neuropsicofarmacologia, Institut de Recerca de l Hospital de la Santa Creu i de Sant Pau, Avgda St Antoni M a Claret, 167, 08025 Barcelona, Spain
    Eur J Pharmacol 576:83-90. 2007
    ..These findings suggest that additional noradrenergic denervation selectively decreases the motor threshold to l-DOPA treatment without modifying the magnitude or the pattern of the motor response to adenosinergic antagonism...
  58. pmc Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease
    Tatyana D Sotnikova
    Department of Cell Biology, Center for Models of Human Disease, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, USA
    PLoS Biol 3:e271. 2005
    ..Identification of dopamine transporter- and dopamine-independent locomotor actions of amphetamines suggests a novel paradigm in the search for prospective anti-Parkinsonian drugs...
  59. ncbi [Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test]
    N Pavon
    Centro Internacional de Restauracion Neurologica, CIREN, La Habana, Cuba
    Rev Neurol 26:915-8. 1998
    ....
  60. ncbi Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease
    Gaëlle Bouchez
    INSERM U930, Laboratory Biophysique médicale and pharmaceutique, UFR Pharmacie, 31 Avenue Monge, Tours, France
    Neurochem Int 52:1332-42. 2008
    ..This cellular approach might be a restorative therapy in Parkinson's disease...
  61. ncbi Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease
    M T Armentero
    Interdepartmental Research Center for Parkinson s Disease CRIMP, IRCCS Neurological Institute C Mondino, Pavia, Italy
    Exp Neurol 212:548-51. 2008
    ....
  62. ncbi Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats
    C Marin
    Laboratori de Neurologia Experimental, Servei de Neurologia, Villarroel 170, 08036, Barcelona, Spain
    J Neural Transm 115:1133-9. 2008
    ..These results suggest that LC depletion might not be involved in the pathophysiology of levodopa-induced motor fluctuations...
  63. ncbi Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
    E Grunblatt
    Eve Topf National Parkinson s Foundation Center for Neurodegenerative Diseases, Technion, Israel
    J Neurochem 77:146-56. 2001
    ....
  64. ncbi Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration
    B Connor
    Department of Pediatrics, Children's Memorial Institute for Education and Research, Northwestern University Medical School, Chicago, Illinois, 60614, USA
    Exp Neurol 169:83-95. 2001
    ..These results suggest that GDNF gene delivery prior to a partial lesion ameliorates damage caused by 6-OHDA in aged rats by inhibiting the degeneration of DA terminals rather than by inducing sprouting of nigrostriatal axons...
  65. ncbi Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease
    M Rodriguez
    Department of Physiology, Department of Anatomy, Faculty of Medicine, Canary University Hospital, La Laguna, Tenerife, Spain
    Exp Neurol 169:163-81. 2001
    ..In some DA subgroups, the cells that contained calbindin but not calretinin were less vulnerable to the neurotoxic effect of 6-OHDA...
  66. ncbi Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat
    M K Barthwal
    Pharmacology Division, Central Drug Research Institute, Lucknow, India
    Redox Rep 6:297-302. 2001
    ..Thus a possible role of nitric oxide in 6-OHDA induced neurodegeneration is suggested...
  67. ncbi Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease
    Kyoko Tsuboi
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA
    Exp Neurol 173:95-104. 2002
    ..This is the first demonstration in vivo that Shh reduces behavioral deficits induced by intrastriatal 6-OHDA lesion and suggests that Shh may be useful in the treatment of disorders that affect the nigrostriatal system, such as PD...
  68. ncbi Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats
    Juan A Gonzalez-Barrios
    Departamento de Fisiologia, Biofisica y Neurociencias, CINVESTAV, Apdo Postal 14 740, 07000 Mexico, D F, Mexico
    Mol Ther 14:857-65. 2006
    ..These data indicate that the neurotensin polyplex holds great promise for the neuroprotective therapy of Parkinson disease...
  69. ncbi CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    Chad Laurie
    Center for Neurovirology and Neurodegenerative Disorders, Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
    J Neuroimmunol 183:60-8. 2007
    ..CD4+ T cells elicited the most significant neuroprotective response while high titers of anti-Cop-1 antibodies showed no effect. These data further support the use of immunomodulatory strategies for Parkinson's disease...
  70. ncbi Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment
    C Zhang
    National Research Council of Canada, Institute for Biological Sciences, Ottawa, Ontario, Canada K1A 0R6
    J Neurosci 21:RC156. 2001
    ....
  71. ncbi Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions
    K P Datla
    Parkinson's Disease Research Unit, Department of Neuroinflammation, Imperial College School of Medicine at Charing Cross Campus, Fulham Palace Road, London W6 8RF, United Kingdom
    Mov Disord 16:424-34. 2001
    ....
  72. ncbi Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions
    W Pirker
    Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, S-17176, Sweden
    Exp Neurol 169:122-34. 2001
    ..Coadministration of (-)-OSU6162 had no apparent influence on these l-DOPA-induced changes in PDyn mRNA expression. The present results suggest that (-)-OSU6162 acts primarily by modifying striatal output via the indirect pathway...
  73. ncbi FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up
    Anne Sophie Hambye
    Department of Nuclear Medicine, CHU Charleroi, Blvd Janson, 92, B 6000 Charleroi, Belgium
    Nucl Med Commun 31:583-9. 2010
    ..To evaluate whether dopamine transport system imaging by FP-CIT single-photon emission computed tomography (SPECT) can be helpful to differentiate idiopathic Parkinson's disease (IPD) from secondary Parkinsonism induced by amiodarone...
  74. ncbi Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism
    H Tohgi
    Department of Neurology, Iwate Medical University, 19 1 Uchimaru Morioka, Iwate 020, Japan
    Eur Neurol 46:1-10. 2001
    ..Absence of 4- to 6-Hz tremor, cogwheel rigidity and the reduction in the SNpc width could be indicators for differentiating VP from IPD...
  75. ncbi [Study of the pre and post-synaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients]
    J Vaamonde
    Servicio de Neurologia, Complejo Hospitalario de Ciudad Real, Ciudad Real
    Neurologia 19:292-300. 2004
    ..Most cases of symptomatic parkinsonism are vascular parkinsonism, but PD may coexist. The differential diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (LBD) is often difficult...
  76. ncbi Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease
    Philipp Mahlknecht
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Neurodegener Dis 7:300-18. 2010
    ..This article aims to review research findings on the value of MRI techniques in the differential diagnosis of neurodegenerative parkinsonian disorders...
  77. ncbi An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism
    Klaus Seppi
    Department of Neurology, Medical University Innsbruck, Austria
    Curr Opin Neurol 18:370-5. 2005
    ..The aim of this article is to review the recent literature on the role of conventional and advanced MRI techniques in the differential diagnosis of neurodegenerative parkinsonian disorders...
  78. ncbi Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain
    J Benito-Leon
    Department of Neurology, Mostoles General Hospital, Ministry of Labor and Social Affairs, Madrid, Spain
    Neurology 62:734-41. 2004
    ..The scarcity of statistics on the incidence of PD and other types of parkinsonism using this methodology led the authors to estimate them in three elderly populations...
  79. ncbi Employment as a welder and Parkinson disease among heavy equipment manufacturing workers
    Gary M Marsh
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    J Occup Environ Med 48:1031-46. 2006
    ..We investigated whether employment as a welder with potential exposure to manganese and other substances is associated with Parkinson disease (PD), parkinsonism or related neurological disorders, or accelerates the age of onset of PD...
  80. ncbi Postoperative parkinsonism and lupus anticoagulant: a model of autoantibody-mediated neurotoxicity in stress
    Wei Hsi Chen
    Department of Neurology, Chang Gung Memorial Hospital, Stroke Biology Research Laboratory, Kaohsiung, Taiwan
    Brain Inj 21:539-43. 2007
    ..Nigrostriatal hypodopaminergism is the fundamental basis in parkinsonism. It may arise secondarily from a variety of disorders but is rarely mentioned shortly after surgery...
  81. ncbi Pineal gland cysts--an overview
    Jelena Bosnjak
    University Department of Neurology, Reference Center for Neurovascular Disorders, Ministry of Health and Social Welfare of the Republic of Croatia, Sestre Milosrdnice University Hospital, Zagreb, Croatia
    Acta Clin Croat 48:355-8. 2009
    ..Tissue sample of the pineal lesion can be obtained by open surgery, stereotaxy and neuroendoscopy...
  82. ncbi [Secondary parkinsonian syndromes]
    G Fenelon
    Service de Neurologie, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris
    Rev Neurol (Paris) 159:3S39-49. 2003
    ..When both a known cause of parkinsonism and Parkinson's disease are present, the cause may be asymptomatic, reveal Parkinson's disease, have an aggravating effect on the underlying disease, or modify its clinical expression...
  83. ncbi Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data
    Kari Swarztrauber
    Parkinson s Disease Research Education and Clinical Center, Portland VA Medical Center, Portland, Oregon, USA
    Mov Disord 20:964-70. 2005
    ..Administrative data are limited in the ability to identify parkinsonism. The ICD-9 CM code, 332.0, which is generally considered the code to identify Parkinson's disease, did not distinguish between parkinsonism and Parkinson's disease...
  84. ncbi Parkinsonism and dystonia caused by the illicit use of ephedrone--a longitudinal study
    Marianna Selikhova
    Institute of Neurology, Reta Lila Weston Institute of Neurological Studies, UCL, United Kingdom
    Mov Disord 23:2224-31. 2008
    ..Ephedrone poisoning should be considered as a possible cause of secondary Parkinsonism in young adults, particularly from Eastern Europe...
  85. ncbi [Utility of dopamine transporter imaging (123-I Ioflupane SPECT) in the assessment of movement disorders]
    A M García Vicente
    Servicio de Medicina Nuclear, Complejo Hospitalario Nuestra Sra de Alarcos, Ciudad Real
    Rev Esp Med Nucl 23:245-52. 2004
    ....
  86. ncbi Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism
    Anna Hotter
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mov Disord 24:S711-20. 2009
    ..This article aims to review recent research findings on the role of advanced MRI techniques in the differential diagnosis of neurodegenerative parkinsonian disorders...
  87. ncbi MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice
    Klaus Seppi
    Department of Neurology, Medical University Innsbruck, Austria
    Parkinsonism Relat Disord 13:S400-5. 2007
    ..Given that olfactory deficits may be a premotor marker of the disease, such methods may eventually evolve into an early screening tool for PD...
  88. ncbi Cavernous hemangioma: a rare cause for secondary parkinsonism: a case report
    Recep Alp
    Faculty of Medicine, Department of Neurology, Kafkas University, Kars, Turkey
    Int J Neurosci 119:2112-7. 2009
    ..We present this patient as a case report, because cavernous angioma with basal ganglia localization is an unusual cause of secondary parkinsonism...
  89. ncbi [Differential diagnosis of parkinsonian syndromes using MRI]
    P Mahlknecht
    Universitätsklinik für Neurologie, Medizinische Universitat Innsbruck, Anichstraße 35, 6020, Innsbruck, Osterreich
    Nervenarzt 81:1168-79. 2010
    ..Furthermore, advances in MRI techniques, such as diffusion-weighted imaging (DWI), have enabled abnormalities in the basal ganglia and infratentorial brain structures in APD to be quantitatively illustrated...
  90. ncbi Parkinson's disease: focus on management alternatives
    L R Young
    University of Tennessee College of Pharmacy, Memphis, 38163, USA
    Am J Manag Care 6:93-113; quiz 114-6. 2000
    ..This activity is designed for physicians, pharmacists, nurses, health planners, directors of managed care organizations, and payers of health services...
  91. pmc Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria
    Njideka U Okubadejo
    Department of Medicine, College of Medicine, University of Lagos, Nigeria
    BMC Neurol 10:1. 2010
    ..Current data on the pattern of parkinsonism and Parkinson's disease in Nigerians are sparse.This database was designed to document the clinical profile of PD in Nigerians, and compare this to prior observations...
  92. ncbi Resting tremor secondary to a pineal cyst: case report and review of the literature
    Jonathan T Morgan
    Division of Pediatric Neurosurgery, Department of Neurosurgery, Schneider Children s Hospital, North Shore Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA
    Pediatr Neurosurg 44:234-8. 2008
    ..Rare symptomatology of secondary parkinsonism attributed to pineal lesions has been previously reported in the literature. We describe an unusual case of a pineal cyst in a patient with the presenting sign of a resting tremor...
  93. ncbi Interleukin-10 gene polymorphism in Parkinson's disease patients
    Monika Bialecka
    Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland
    Arch Med Res 38:858-63. 2007
    ..To prove this hypothesis, two DNA polymorphisms at IL-10 promoter (-1082 and -519) were examined in sporadic PD patients...
  94. pmc Progressive anarthria with secondary parkinsonism: a clinico-pathological case report
    E Broussolle
    Neurometabolic Unit, Antiquaille Hospital, Lyon, France
    J Neurol Neurosurg Psychiatry 55:577-80. 1992
    ..This original case reinforces the view that there are different entities of the syndrome of progressive aphasia which can be identified on the basis of clinical, neuroimaging and anatomical data...
  95. ncbi Identifying incident cases of parkinsonism among veterans using a tertiary medical center
    Donna White
    Houston Center for Quality of Care and Utilization Studies, Michael E DeDebakey Veterans Affair Medical Center, Houston, Texas, USA
    Mov Disord 22:915-23. 2007
    ....
  96. ncbi Vascular parkinsonism: a distinct, heterogeneous clinical entity
    M Demirkiran
    Cukurova University, School of Medicine, Department of Neurology, Adana, Turkey
    Acta Neurol Scand 104:63-7. 2001
    ..The aim of this study was to define the symptoms and signs of suspected vascular parkinsonism (VP) which is still a debatable concept...
  97. ncbi Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation
    Arianna Bellucci
    Division of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
    J Neurochem 106:560-77. 2008
    ..These changes may be counteracted by the block of DA uptake and by dopaminergic agonist treatment...
  98. ncbi Atypical antipsychotic use and risk of fracture in persons with Parkinsonism
    David D Dore
    i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts, USA
    Mov Disord 24:1941-8. 2009
    ..2-2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism...
  99. ncbi [Diagnosis and treatment of patients with parkinsonism in nursing homes: how to improve quality?]
    Jan Petter Larsen
    Nasjonalt kompetansesenter for bevegelsesforstyrrelser, Nevrologisk avdeling, Sentralsjukehuset i Rogaland, Postboks 8100, 4068 Stavanger
    Tidsskr Nor Laegeforen 125:1669-71. 2005
    ..Studies have shown that diagnosing and treating patients with parkinsonism in nursing homes could be improved. Parkinson's disease is the most important cause of parkinsonism...
  100. ncbi [Parkinsonism probably induced by manganese]
    E Duran
    Servicio de Neurologia, Hospital Universitario Virgen Macarena, Sevilla, Espana
    Rev Neurol 33:434-6. 2001
    ..Therefore a battery of diagnostic tests should be done before classification as idiopathic Parkinson s disease...
  101. ncbi The Parkinson chimera
    Andrew J Lees
    Reta Lila Weston Institute for Neurological Studies, Institute of Neurology, UCL and the National Hospital for Neurology and Neurosurgery, Queen Square, London
    Neurology 72:S2-11. 2009
    ....

Research Grants63

  1. Divalent Metal Transporter: Role in Manganese Toxicity
    JEROME ROTH; Fiscal Year: 2004
    ....
  2. ROLE OF PROTEASOMAL DYSFUNCTION IN PARKINSON'S DISEASE
    KEVIN MCNAUGHT; Fiscal Year: 2008
    ..These studies will test our hypothesis that inadequate proteasomal function underlies both vulnerability and degeneration of the SNc in sporadic Parkinson's disease. ..
  3. Blood Brain Barrier Dysfunction in Parkinson's Diseases
    Paul M Carvey; Fiscal Year: 2010
    ..These findings would provide an entirely new hypothesis for progression pa hogenesis and identify new targets for therapeutic intervention in PD designed arou d affecting BBB integrity. ..
  4. Sleep and Nocturnal Endocrine Function in MDMA User
    Una McCann; Fiscal Year: 2007
    ..Results from the proposed studies will help better define the functional consequences of MDMA exposure in humans, and could shed light on the roles of 5-HT and DA in sleep and nocturnal endocrine function. ..
  5. Gluthathione Depletion /Mitochondrial Complex I Dysfunct
    Julie Andersen; Fiscal Year: 2006
    ..unreadable]..
  6. Organochlorine pesticide, PCBs, and Parkinsons
    Alberto Ascherio; Fiscal Year: 2007
    ..Finally, the long follow-up period will allow the investigation of long-term effects of exposure. ..
  7. AIDS Neurotherapeutics and BBB Drug Efflux
    William Pardridge; Fiscal Year: 2007
    ..This work provides the basis for future drug discovery of AET blockers, which can be used as co-drugs to increase CNS penetration of HAART drugs. ..
  8. F-18 Synthesizer
    Anna Liisa Brownell; Fiscal Year: 2007
    ..The synthesizer must balance a number of factors in the design to fulfill requirements for performance, accessibility and fitness to the research environment. [unreadable] [unreadable] [unreadable]..
  9. DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS
    Jeffrey Kordower; Fiscal Year: 2006
    ..This application will determine whether potent dopaminergic gene therapies influence dyskinesias in the best animal model of PD. ..
  10. Dopamine D2 and Adenosine A2A roles:Tremulous Movements
    John Salamone; Fiscal Year: 2007
    ..abstract_text> ..
  11. Development of NET-Selective Piperidine-Based PET Ligand
    Anna Liisa Brownell; Fiscal Year: 2006
    ..4. Promising PET imaging agents will be studied in cell toxicity and animal models during the second year. ..
  12. CASPASES, MITOCHONDRIAL FUNCTION AND PARKINSON'S DISEASE
    Anumantha Kanthasamy; Fiscal Year: 2006
    ..abstract_text> ..
  13. Novel Approaches for in vivo of mGluRs
    Anna Liisa Brownell; Fiscal Year: 2006
    ..abstract_text> ..
  14. HIV-1 protein neurotoxicity and ethanol pre-conditioning
    Michael Collins; Fiscal Year: 2006
    ..abstract_text> ..
  15. Developmental Pyrethroid Exposure and ADHD
    Jason Richardson; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  16. In Vivo Imaging of Post-Traumatic Cerebral Amyloid Deposition
    Marvin Bergsneider; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  17. Effort-related Functions of Nucleus Accumbens Adenosine A2A Receptors
    John D Salamone; Fiscal Year: 2010
    ....
  18. In Vivo CSF Shunt Hydrodynamics in Hydrocephalus
    Marvin Bergsneider; Fiscal Year: 2010
    ..Documenting definitive evidence of the tuned-dynamic absorber model could have fundamental implications to all ICP disorders. ..
  19. TH and GTPCHI gene therapy for Parkinson's disease
    Jeffrey H Kordower; Fiscal Year: 2010
    ..These studies will determine the safety and efficacy of gene delivery of LDOPA and determine whether this approach is appropriate for clinical trials. ..
  20. NEUROPROTECTIVE STRATEGIES AGAINST OXIDATIVE DAMAGE
    Anumantha Kanthasamy; Fiscal Year: 2009
    ....
  21. Effects of Nicotine on Human Cerebral Transmitters
    EDWARD DOMINO; Fiscal Year: 2008
    ..This research will provide direct proof of basic neuroscience studies, which indicate nicotine releases neurotransmitters such as dopamine and endogenous opioids. [unreadable] [unreadable] [unreadable]..
  22. Olfaction as a Biomarker for Parkinson's Disease
    Anna Liisa Brownell; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  23. Neurotoxicity of sterol glucosides: role in ALS-PDC
    Christopher Shaw; Fiscal Year: 2008
    ..Our long-term Aims are to identify the causative molecule(s) in ALS-PDC which can share common basis with the rest of the neurodegenerative diseases. [unreadable] [unreadable] [unreadable]..
  24. Reconstruction of nigrostriatal pathway by photopolymerized neurotrophin...
    Kimberly Bjugstad; Fiscal Year: 2008
    ..While we are using an animal model of PD to test this hypothesis, if successful, it could have implications for other neurodegenerative disorders, including Huntington's Disease or stroke. [unreadable] [unreadable] [unreadable]..
  25. Nicotine and Cognition in Parkinsonism
    Jay Schneider; Fiscal Year: 2008
    ..Information obtained from these studies will hopefully lead to more efficient design of nicotinic therapeutics for patients with a variety of cognitive disorders. ..
  26. Non-Viral Gene Targeting to the Brain
    William Pardridge; Fiscal Year: 2008
    ..abstract_text> ..
  27. Environmental, Genetic and Cellular Determinants of Parkinson's Disease
    James Langston; Fiscal Year: 2007
    ..Success in these endeavors could lead to new strategies for treatment and even disease prevention...
  28. Textile Industry Exposures and Breast Cancer in Women
    Harvey Checkoway; Fiscal Year: 2006
    ..The results of our study should generate important new epidemiologic information that may suggest breast cancer prevention strategies in women textile workers and other women with similar exposures. ..
  29. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  30. LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MODEL
    Marina Emborg; Fiscal Year: 2003
    ..These studies will serve as the preclinical foundation to determine whether this in vivo method to deliver these potent trophic factor and antiapoptotic genes will be suitable for testing in patients with PD. ..
  31. FMRI ANALYSIS OF IMPLICIT MEMORY IN NORMAL AGING
    Debra Fleischman; Fiscal Year: 2004
    ....
  32. 9th International Neurotoxicology Assoc (INA9) Meeting
    Michael Aschner; Fiscal Year: 2003
    ....
  33. MOTOR EFFECTS OF ATYPICAL ANTIPSYCHOTICS
    John Salamone; Fiscal Year: 2003
    ..Taken together, the results of these experiments will help to identify the pharmacological characteristics and brain circuits that underlie the motor effects of clozapine. ..
  34. Epidemiology of cognitive dysfunction and Parkinson's
    Alberto Ascherio; Fiscal Year: 2003
    ..The interview will be conducted by telephone and take approximately 20-25 minutes to complete. As part of the proposed project, we will administer these tests to men and women with PD and age-matched healthy controls. ..
  35. TREATMENTS FOR INSOMNIA
    Jerome Yesavage; Fiscal Year: 2003
    ..This five-year application will ultimately include 90 treatment subjects aged >60 years (three groups of 30 each). ..
  36. Pre-diagnostic markers of infection and risk of MS
    Alberto Ascherio; Fiscal Year: 2009
    ....
  37. ADAPTIVE BEHAVIOR AND BRAIN MONOAMINES
    Michael Zigmond; Fiscal Year: 2002
    ..The longer-term objectives of this project are to provide new insights into the basic neurobiology of LC neurons and the psychopathology that develops from chronic stress. ..
  38. POOLING OF COHORT STUDIES ON DIET & CORONARY DISEASE
    Alberto Ascherio; Fiscal Year: 2001
    ..In addition, we will ask whether nerve regeneration is altered by administration of these cytokines. This could have obvious health benefits to the millions of diabetics that suffer from nerve damage. ..
  39. BEHAVIORAL EFFECTS OF NIGRAL D1 ANTAGONISM
    John Salamone; Fiscal Year: 2001
    ....
  40. BASIS OF SYNAPTIC PATHOLOGY IN ALZHEIMERS DISEASE
    Eliezer Masliah; Fiscal Year: 2001
    ..These studies will help to better understand the mechanisms of synaptic pathology in AD and to develop potential neuroprotective agents that will operate by enhancing the GT activity. ..
  41. AGING AND DOPAMINE GRAFTS IN PARKINSONIAN MONKEYS
    Timothy Collier; Fiscal Year: 2003
    ....
  42. REGULATION OF BBB GLUT1 GLUCOSE TRANSPORTER
    William Pardridge; Fiscal Year: 2002
    ..These studies will provide insight into molecular mechanisms of regulation of a step crucial to the maintenance of cerebral intermediary metabolism, i.e., the continuous transport of glucose across the blood-brain barrier in vivo. ..
  43. Subcortical Estrogen Effect on The Hippocampus
    Csaba Leranth; Fiscal Year: 2005
    ..cholinergic and GABAergic septo-hippocampal neurons involved in mediating estrogenic effect to the hippocampus? and (d) Do SUM neurons mediate estrogenic effect to the hippocampus directly or indirectly, via the MSDB? ..
  44. Antisense imaging of brain gene expression in vivo
    William Pardridge; Fiscal Year: 2005
    ..This technology could be extended to humans and to other organs. At present, there is no parallel technology that enables the non-invasive in vivo imaging of "any gene in any person," which is the goal of this work. ..
  45. ROLE OF IRON AND GLUTATHIONE IN PARKINSON'S DISEASE
    Julie Andersen; Fiscal Year: 2005
    ....
  46. Developmental Pyrethroid Exposure and Parkinsons Disease
    Jason Richardson; Fiscal Year: 2005
    ....
  47. Developmental Stress and Vulnerability to Brain Injury
    Michael Zigmond; Fiscal Year: 2004
    ..Moreover, the methods and reagents that we develop will be made available to others in the field. ..
  48. Estrogenic Effect on Hippocampal Theta Rhythm and Memory
    Csaba Leranth; Fiscal Year: 2004
    ....
  49. DIETARY ETIOLOGIES OF MULTIPLE SCLEROSIS AND PARKINSONS
    Alberto Ascherio; Fiscal Year: 2001
    ..By the end of the follow-up, we project a total of 461 confirmed cases of MS and 380 confirmed cases of PD. We will have sufficient poser to evaluate a series of specific hypotheses with substantial public health implications. ..
  50. Time-lines of neural degeneration in ALS-PDC mouse model
    Christopher A Shaw; Fiscal Year: 2010
    ..These data will provide therapeutic targets to prevent or halt the progression of neurodegeneration. ..
  51. Iron dysregulation and Parkinson's disease
    Julie Andersen; Fiscal Year: 2009
    ..Through a better understanding of the possible intrinsic and extrinsic mechanisms by which iron dysregulation occurs in the Parkinsonian SN, our findings may aid in the development of novel therapies for the disease. ..
  52. A HEMODYNAMIC MODEL OF INTRACRANIAL PRESSURE DYNAMICS
    Marvin Bergsneider; Fiscal Year: 2002
    ..An improved understanding of these disorders will offer new and better treatment modalities for millions of affected patients. ..
  53. Prenatal LPS-induced changes in gene expression
    Paul Carvey; Fiscal Year: 2005
    ..The results of these studies will also provide a unique opportunity to determine if prenatal neurotoxin exposure can permanently alter genes that increase the risk of neurodegenerative disease in later life. ..
  54. GENETICS OF MPTP-INDUCED PARKINSONISM
    Richard Smeyne; Fiscal Year: 2009
    ..This identification of GSTp2 as a candidate gene could also lead to the identification of diagnostic measures and point to potential therapies for early intervention in this devastating illness. ..
  55. Development Stress, Exercise, and Vulnerability to Neuronal Injury
    Michael J Zigmond; Fiscal Year: 2010
    ....
  56. TRAINING FACULTY TO TEACH SURVIVAL SKILLS AND ETHICS
    Michael Zigmond; Fiscal Year: 2005
    ..Efforts will be made to promote diversity with regard to the demographics of both the workshop participants and those they serve. Instruction will be provided by the PI's together with a highly qualified group of trainers. ..
  57. 2005 Gordon Conference on Catecholamines
    David Sulzer; Fiscal Year: 2005
    ..abstract_text> ..
  58. GM1 Ganglioside Effects on Parkinson's Disease
    Jay Schneider; Fiscal Year: 2007
    ..Working hypothesis: Long-term GM1 use will stabilize symptoms or slow the progression of symptoms in PD patients and this may be accompanied by reduced loss of striatal DA terminals over time. [unreadable] [unreadable]..
  59. Light Treatment for Sleep/Wake Disturbances AD
    Jerome Yesavage; Fiscal Year: 2008
    ..Outcome will be documented by objective circadian activity rhythm parameters and standard sleep/wake measures both assessed by actigraphy. ..
  60. GENE/ENVIRONMENT INTERACTIONS IN PARKINSON'S DISEASE
    Harvey Checkoway; Fiscal Year: 2004
    ..Furthermore, this project may ultimately serve as a model approach for investigating the complex interplay between environmental exposures and host factors on risk for neurodegenerative disorders. ..
  61. MICROPET FOR ANIMAL STUDIES
    Anna Liisa Brownell; Fiscal Year: 2001
    ..Our previous experience in developing and operating PET systems will be of great benefit in the expansion of the facility. ..
  62. BLOOD BRAIN BARRIER LARGE NEUTRAL AMINO ACID TRANSPORTER
    William Pardridge; Fiscal Year: 2003
    ..These studies will provide new molecular biological information on a crucial transporter at the blood-brain barrier that regulates the supply in the brain of essential amino acids. ..